CT-guided High-Dose-Rate Brachytherapy versus Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma

Published Online:https://doi.org/10.1148/radiol.232044

In treatment-naive patients with unresectable hepatocellular carcinoma, CT-guided high-dose-rate brachytherapy led to improved survival outcomes compared with transarterial chemoembolization.

Background

CT-guided high-dose-rate (HDR) brachytherapy (hereafter, HDR brachytherapy) has been shown to be safe and effective for patients with unresectable hepatocellular carcinoma (HCC), but studies comparing this therapy with other local-regional therapies are scarce.

Purpose

To compare patient outcomes of HDR brachytherapy and transarterial chemoembolization (TACE) in patients with unresectable HCC.

Materials and Methods

This multi-institutional retrospective study included consecutive treatment-naive adult patients with unresectable HCC who underwent either HDR brachytherapy or TACE between January 2010 and December 2022. Overall survival (OS) and progression-free survival (PFS) were compared between patients matched for clinical and tumor characteristics by propensity score matching. Not all patients who underwent TACE had PFS available; thus, a different set of patients was used for PFS and OS analysis for this treatment. Hazard ratios (HRs) were calculated from Kaplan-Meier survival curves.

Results

After propensity matching, 150 patients who underwent HDR brachytherapy (median age, 71 years [IQR, 63–77 years]; 117 males) and 150 patients who underwent TACE (OS analysis median age, 70 years [IQR, 63–77 years]; 119 male; PFS analysis median age, 68 years [IQR: 63–76 years]; 119 male) were analyzed. Hazard of death was higher in the TACE versus HDR brachytherapy group (HR, 4.04; P < .001). Median estimated PFS was 32.8 months (95% CI: 12.5, 58.7) in the HDR brachytherapy group and 11.6 months (95% CI: 4.9, 22.7) in the TACE group. Hazard of disease progression was higher in the TACE versus HDR brachytherapy group (HR, 2.23; P < .001).

Conclusion

In selected treatment-naive patients with unresectable HCC, treatment with CT-guided HDR brachytherapy led to improved OS and PFS compared with TACE.

© RSNA, 2024

Supplemental material is available for this article.

See also the editorial by Chapiro in this issue.

References

  • 1. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol 2020;72(2):250–261. Crossref, MedlineGoogle Scholar
  • 2. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 2022;76(3):681–693. Crossref, MedlineGoogle Scholar
  • 3. Piscaglia F, Ogasawara S. Patient selection for transarterial chemoembolization in hepatocellular carcinoma: importance of benefit/risk assessment. Liver Cancer 2018;7(1):104–119. Crossref, MedlineGoogle Scholar
  • 4. Rou WS, Lee BS, Moon HS, Lee ES, Kim SH, Lee HY. Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. World J Gastroenterol 2014;20(22):6995–7004. Crossref, MedlineGoogle Scholar
  • 5. Ricke J, Wust P, Stohlmann A, et al. CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys 2004;58(5):1496–1505. Crossref, MedlineGoogle Scholar
  • 6. Ricke J, Wust P, Wieners G, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol 2004;15(11):1279–1286. Crossref, MedlineGoogle Scholar
  • 7. Collettini F, Schnapauff D, Poellinger A, et al. Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7 cm) and very large (>7 cm) tumours. Eur Radiol 2012;22(5):1101–1109. Crossref, MedlineGoogle Scholar
  • 8. Collettini F, Singh A, Schnapauff D, et al. Computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of metastases adjacent to the liver hilum. Eur J Radiol 2013;82(10):e509–e514. Crossref, MedlineGoogle Scholar
  • 9. Mohnike K, Steffen IG, Seidensticker M, et al. Radioablation by image-guided (HDR) brachytherapy and transarterial chemoembolization in hepatocellular carcinoma: a randomized phase II trial. Cardiovasc Intervent Radiol 2019;42(2):239–249. Crossref, MedlineGoogle Scholar
  • 10. Mohnike K, Wolf S, Damm R, et al. Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy: complications and risk factors. Strahlenther Onkol 2016;192(5):288–296. Crossref, MedlineGoogle Scholar
  • 11. Mohnike K, Wieners G, Schwartz F, et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys 2010;78(1):172–179. Crossref, MedlineGoogle Scholar
  • 12. Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol 2021;44(12):1851–1867. Crossref, MedlineGoogle Scholar
  • 13. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30(1):52–60. Crossref, MedlineGoogle Scholar
  • 14. Hansen BB, Klopfer SO. Optimal full matching and related designs via network flows. J Comput Graph Stat 2006;15(3):609–627. CrossrefGoogle Scholar
  • 15. Borgan Ø. Modeling survival data: extending the Cox model. Terry M. Therneau and Patricia M. Grambsch, Springer-Verlag, New York, 2000. No. of pages: xiii + 350. Price: $69.95. ISBN 0-387-98784-3. Stat Med 2001;20(13):2053–2054. CrossrefGoogle Scholar
  • 16. van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat Softw 2011;45(3):1–67. Google Scholar
  • 17. Pishgar F, Greifer N, Leyrat C, Stuart E. MatchThem: matching and weighting after multiple imputation. R J 2021;13(2):292–305. CrossrefGoogle Scholar
  • 18. Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015;35(9):2155–2166. Crossref, MedlineGoogle Scholar
  • 19. Han G, Berhane S, Toyoda H, et al. Prediction of survival among patients receiving transarterial chemoembolization for hepatocellular carcinoma: a response-based approach. Hepatology 2020;72(1):198–212. Crossref, MedlineGoogle Scholar
  • 20. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 2016;64(1):106–116. Crossref, MedlineGoogle Scholar
  • 21. Thomas HR, Feng M. Stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma. Curr Hepatol Rep 2021;20(1):12–22. CrossrefGoogle Scholar
  • 22. Dawson LA. Overview: where does radiation therapy fit in the spectrum of liver cancer local-regional therapies? Semin Radiat Oncol 2011;21(4):241–246. Crossref, MedlineGoogle Scholar
  • 23. Scorsetti M, Arcangeli S, Tozzi A, et al. Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 2013;86(2):336–342. Crossref, MedlineGoogle Scholar
  • 24. Ricke J, Wust P. Computed tomography-guided brachytherapy for liver cancer. Semin Radiat Oncol 2011;21(4):287–293. Crossref, MedlineGoogle Scholar
  • 25. Schnapauff D, Collettini F, Steffen I, et al. Activity-based cost analysis of hepatic tumor ablation using CT-guided high-dose rate brachytherapy or CT-guided radiofrequency ablation in hepatocellular carcinoma. Radiat Oncol 2016;11(1):26. Crossref, MedlineGoogle Scholar

Article History

Received: Aug 11 2023
Revision requested: Oct 11 2023
Revision received: Nov 15 2023
Accepted: Dec 18 2023
Published online: Feb 06 2024